GlassScriptPhysician profile
David Lee Hotchkin
NPI 1245340538
$65,132.58
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,703 · 2020: $7,582 · 2021: $7,505 · 2022: $6,790 · 2023: $16K · 2024: $5,652 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $6,350 · Travel and Lodging: $2,479 · Food and Beverage: $1,547 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,160.00 |
| Consulting Fee | $6,350.00 |
| Travel and Lodging | $2,479.17 |
| Food and Beverage | $1,546.92 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64,045.22 | 2019-2025 | Ofev |
| Medtronic, INC. | $212.75 | 2024 | Mc3 Nautilus(Tm) Ecmo Oxygenator |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Intuitive Surgical, INC. | $134.72 | 2019 | |
| Gilead Sciences, INC. | $130.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $98.77 | 2023-2024 | Fasenra |
| Genentech, INC. | $74.28 | 2022-2025 | |
| Abiomed | $59.07 | 2023-2025 | Impella |
| Genzyme Corporation | $32.48 | 2025 | |
| United Therapeutics Corporation | $29.28 | 2023 | |
| Baxter Healthcare | $25.47 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $25.15 | 2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $17.79 | 2024 | Dupixent |
| Insmed, INC. | $16.24 | 2023 | Arikayce |
| Boston Scientific Corporation | $15.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.39 | 2023 | Nucala |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hotchkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.